Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 29.27% is 11% below its 5-year average of 32.80%, around the middle of its 5-year range (4.22%–43.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 25.48% above its 12-month average of 23.32%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.27%.
DEBT TO ASSETS RATIO
29.27%
DEBT TO ASSETS RATIO AVG TTM
23.32%
DEBT TO ASSETS RATIO AVG 3Y
36.03%
DEBT TO ASSETS RATIO AVG 5Y
32.80%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+25.48%
CURRENT VS 3Y AVG
-18.76%
CURRENT VS 5Y AVG
-10.77%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 868 covered companies
CURRENT VS SECTOR MEDIAN
+32418.46%
vs the sector median at left
Maravai LifeSciences Holdings, Inc.
Market Cap
$2.27B
Debt to Assets Ratio
29.27%
TTM Avg
23.32%
3Y Avg
36.03%
5Y Avg
32.80%
Market Cap
$2.28B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.33B
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.34B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.36B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. (MRVI) | $2.27B | 29.27% | 23.32% | 36.03% | 32.80% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 0.11% | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.32B | 0.25% | N/A | N/A | N/A |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 0.20% | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | 0.11% | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 0.30% | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | 0.13% | N/A | N/A | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.17B | 0.00% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.38B | 0.05% | N/A | N/A | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.14B | 0.35% | N/A | N/A | N/A |
Debt/Assets
29.3%
Debt/Equity
0.86
Current Ratio
4.05
Interest Coverage
-0.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 29.27% |
| 2026-03-31 | 37.98% |
| 2025-12-31 | 4.62% |
| 2025-09-30 | 4.22% |
| 2025-06-30 | 40.54% |
| 2025-03-31 | 34.04% |
| 2024-12-31 | 37.36% |
| 2024-09-30 | 43.90% |
| 2024-06-30 | 38.81% |
| 2024-03-31 | 38.95% |
| 2023-12-31 | 41.07% |
| 2023-09-30 | 27.11% |
| 2023-06-30 | 27.26% |
| 2023-03-31 | 26.08% |
| 2022-12-31 | 25.64% |
| 2022-09-30 | 23.75% |
| 2022-06-30 | 24.56% |
| 2022-03-31 | 29.19% |
| 2021-12-31 | 29.99% |
| 2021-09-30 | 30.98% |
| 2021-06-30 | 36.73% |
| 2021-03-31 | 43.61% |
| 2020-12-31 | 46.49% |
| 2020-09-30 | 62.84% |
| 2019-12-31 | 67.53% |
